Patents by Inventor Gordon W. Laurie
Gordon W. Laurie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220305083Abstract: This application generally relates to stable peptide compositions and kits comprising low levels of buffering and chelating agents, and methods of using the same.Type: ApplicationFiled: November 4, 2021Publication date: September 29, 2022Inventors: Gordon W. Laurie, Marc G. Odrich, Michelle Carpenter, Thomas R. Gadek, Paul A. Laskar
-
Publication number: 20220160838Abstract: Compositions and methods for regenerating pancreatic islet viability and/or cell proliferation in vitro, ex vivo, and/or in vivo; and/or for regenerating glucose-stimulated insulin secretion; and/or for regenerating viability and/or cell proliferation of a transplanted pancreatic islets; and/or for preventing and/or inhibiting rejection of a transplanted islets; and/or for pancreatic islet transplantation; and/or for treating a symptom of a condition, disorder, or disease associated with abnormal insulin responsiveness to glucose are provided. In some embodiments, the compositions include a peptide and/or a pharmaceutically acceptable salt thereof, and/or a biologically active fragment, analog, or derivative thereof, wherein the peptide, the pharmaceutically acceptable salt thereof, and/or the biologically active fragment, analog, or derivative thereof has an amino acid sequence of any of SEQ ID NOs: 1-60, or any combination thereof.Type: ApplicationFiled: March 13, 2020Publication date: May 26, 2022Applicant: University of Virginia Patent FoundationInventors: Gordon W. Laurie, Kenneth Brayman, Preeti Chhabra, Mingyang Ma, Karina Teixeira, Thomas R. Gadek
-
Publication number: 20210231684Abstract: The present invention provides compositions and methods for identifying subjects suffering from dry eye that can be treated by topical administration of a composition comprising lacritin or a bioactive fragment thereof. The application discloses in part that a ˜90 KDa deglycanated form of syndecan-1 is abundant in tears of normal individuals but not individuals suffering from dry eye, whereas a ˜25 kDa syndecan-1 fragment is detectable in dry, but not normal tears.Type: ApplicationFiled: October 30, 2020Publication date: July 29, 2021Inventor: Gordon W. Laurie
-
Publication number: 20200174017Abstract: The present invention provides compositions and methods for identifying subjects suffering from dry eye that can be treated by topical administration of a composition comprising lacritin or a bioactive fragment thereof. The application discloses in part that a ˜90 KDa deglycanated form of syndecan-1 is abundant in tears of normal individuals but not individuals suffering from dry eye, whereas a ˜25 kDa syndecan-1 fragment is detectable in dry, but not normal tears.Type: ApplicationFiled: July 12, 2019Publication date: June 4, 2020Inventor: Gordon W. Laurie
-
Publication number: 20190381136Abstract: This application generally relates to stable peptide compositions and kits comprising low levels of buffering and chelating agents, and methods of using the same.Type: ApplicationFiled: February 20, 2018Publication date: December 19, 2019Inventors: Gordon W. Laurie, Marc G. Odrich, Michelle Carpenter, Thomas R. Gadek, Paul A. Laskar
-
Patent number: 10393755Abstract: The present invention provides compositions and methods for identifying subjects suffering from dry eye that can be treated by topical administration of a composition comprising lacritin or a bioactive fragment thereof. The application discloses in part that a ˜90 KDa deglycanated form of syndecan-1 is abundant in tears of normal individuals but not individuals suffering from dry eye, whereas a ˜25 kDa syndecan-1 fragment is detectable in dry, but not normal tears.Type: GrantFiled: June 1, 2017Date of Patent: August 27, 2019Assignee: University of Virginia Patent FoundationInventor: Gordon W. Laurie
-
Patent number: 10302658Abstract: The present invention provides compositions and methods for identifying subjects suffering from dry eye that can be treated by topical administration of a composition comprising lacritin or a bioactive fragment thereof. The application discloses in part that a ˜90 KDa deglycanated form of syndecan-1 is abundant in tears of normal individuals but not individuals suffering from dry eye, whereas a ˜25 kDa syndecan-1 fragment is detectable in dry, but no normal tears.Type: GrantFiled: March 11, 2015Date of Patent: May 28, 2019Assignee: University of Virginia Patent FoundationInventor: Gordon W. Laurie
-
Publication number: 20180094137Abstract: Disclosed herein are novel methods and compositions for targeting ocular diseases. One aspect relates to a contact lens comprising an elastin-like peptide (ELP) component and optionally a therapeutic agent. Also provided are methods for treating ocular diseases comprising administering a contact lens of the disclosure to a subject in need thereof.Type: ApplicationFiled: March 31, 2014Publication date: April 5, 2018Applicant: University of virginia Patent FoundationInventors: John Andrew Mackay, Wan Wang, Gordon W. Laurie
-
Publication number: 20170322226Abstract: The present invention provides compositions and methods for identifying subjects suffering from dry eye that can be treated by topical administration of a composition comprising lacritin or a bioactive fragment thereof. The application discloses in part that a ˜90 KDa deglycanated form of syndecan-1 is abundant in tears of normal individuals but not individuals suffering from dry eye, whereas a ˜25 kDa syndecan-1 fragment is detectable in dry, but not normal tears.Type: ApplicationFiled: June 1, 2017Publication date: November 9, 2017Inventor: Gordon W. LAURIE
-
Publication number: 20170322227Abstract: The present invention provides compositions and methods for identifying subjects suffering from dry eye that can be treated by topical administration of a composition comprising lacritin or a bioactive fragment thereof. The application discloses in part that a ˜90 KDa deglycanated form of syndecan-1 is abundant in tears of normal individuals but not individuals suffering from dry eye, whereas a ˜25 kDa syndecan-1 fragment is detectable in dry, but not normal tears.Type: ApplicationFiled: June 1, 2017Publication date: November 9, 2017Inventor: Gordon W. LAURIE
-
Publication number: 20170176457Abstract: The present invention provides compositions and methods for identifying subjects suffering from dry eye that can be treated by topical administration of a composition comprising lacritin or a bioactive fragment thereof. The application discloses in part that a ˜90 KDa deglycanated form of syndecan-1 is abundant in tears of normal individuals but not individuals suffering from dry eye, whereas a ˜25 kDa syndecan-1 fragment is detectable in dry, but no normal tears.Type: ApplicationFiled: March 11, 2015Publication date: June 22, 2017Inventor: Gordon W. LAURIE
-
Patent number: 7932227Abstract: The present invention relates to methods and compositions useful for the regulation of lacritin, syndecan, and lacritin-syndecan interactions and the signaling pathway downstream of lacritin-syndecan interactions. The invention also relates to regulating lacritin-syndecan interaction to regulate ocular cell survival in response to an insult or injury, in protecting against ocular inflammation, and in promoting ocular wound repair.Type: GrantFiled: September 17, 2008Date of Patent: April 26, 2011Assignee: University of Virginia Patent FoundationInventors: Gordon W. Laurie, Peisong Ma
-
Publication number: 20110065189Abstract: The present invention relates to methods and compositions useful for the regulation of lacritin, syndecan, and lacritin-syndecan interactions and the signaling pathway downstream of lacritin-syndecan interactions. The invention also relates to regulating lacritin-syndecan interaction to regulate ocular cell survival in response to an insult or injury, in protecting against ocular inflammation, and in promoting ocular wound repair.Type: ApplicationFiled: November 17, 2010Publication date: March 17, 2011Applicant: UNIVERSITY OF VIRGINIA PATENT FOUNDATIONInventors: Gordon W. Laurie, Peisong Ma
-
Patent number: 7648964Abstract: The present invention relates to the use of lacritin, and fragments, derivatives, and homologs thereof, and nucleic acid sequences encoding that protein. The invention relates to the use of lacritin as a growth factor human corneal epithelial cells and other select epithelial cells. The invention also relates to the use of lacritin in promoting ocular cell survival in response to an insult or injury, in protecting against ocular inflammation, and in promoting ocular wound repair.Type: GrantFiled: May 6, 2005Date of Patent: January 19, 2010Assignee: University of Virginia Patent FoundationInventors: Gordon W. Laurie, Jiahu Wang
-
Publication number: 20090312252Abstract: The present invention provides recombinant proteins with antimicrobial activity and methods for treating animals including humans by administering the novel recombinant proteins. In particular, the invention provides methods for treating and/or preventing microbial diseases and infections using lacritin and homologs, fragments, modifications, and derivatives thereof.Type: ApplicationFiled: September 13, 2007Publication date: December 17, 2009Applicant: UNIVERSITY OF VIRGINIA PATENT FOUNDATIONInventors: Robert L. McKown, Ronald W. Raab, Gordon W. Laurie
-
Patent number: 7459440Abstract: The present invention relates to a novel lacrimal gland protein (designated lacritin) and the nucleic acid sequences encoding that protein. Lacritin has activity as a growth factor on both human corneal epithelial cells and on the lacrimal acinar cells that produce it. Accordingly, one embodiment of the present invention is directed to the use of lacritin to treat Dry Eye and other disorders requiring the wetting of the eye.Type: GrantFiled: March 6, 2007Date of Patent: December 2, 2008Assignee: University of Virginia Patent FoundationInventors: Gordon W. Laurie, Sandhya Sanghi, Kumar Rajesh, Angela J. Lumsden
-
Patent number: 7320870Abstract: The present invention relates to a novel lacrimal gland protein (designated lacritin) and the nucleic acid sequences encoding that protein. Lacritin has activity as a growth factor on both human corneal epithelial cells and on the lacrimal acinar cells that produce it. Accordingly, one embodiment of the present invention is directed to the use of lacritin to treat Dry Eye and other disorders requiring the wetting of the eye.Type: GrantFiled: March 6, 2007Date of Patent: January 22, 2008Assignee: University of Virginia Patent FoundationInventors: Gordon W. Laurie, Sandhya Sanghi, Kumar Rajesh, Angela J. Lumsden
-
Publication number: 20040081984Abstract: The present invention relates to a novel lacrimal gland protein (designated lacritin) and the nucleic acid sequences encoding that protein. Lacritin has activity as a growth factor on both human corneal epithelial cells and on the lacrimal acinar cells that produce it Accordingly, one embodiment of the present invention is directed to the use of lacritin to treat Dry Eye and other disorders requiring the wetting of the eye.Type: ApplicationFiled: August 19, 2003Publication date: April 29, 2004Inventors: Gordon W. Laurie, Sandhya Sanghi, Kumar Rajesh, Angela J. Lumsden
-
Patent number: 5895812Abstract: The present invention relates to a novel polypeptide which has secretion enhancing activity on lacrimal and parotid gland cells, monoclonal antibodies thereto, and methods of diagnosising Sjorgren's syndrome using these antibodies.Type: GrantFiled: May 1, 1995Date of Patent: April 20, 1999Assignee: The University of Virginia Alumni Patent FoundationInventors: Gordon W. Laurie, Rebecca A. Ogle, J. Douglas Glass
-
Patent number: 5696229Abstract: The present invention provides novel cell adhesion peptides.Type: GrantFiled: March 16, 1995Date of Patent: December 9, 1997Assignee: The University of Virginia Patent FoundationInventors: Gordon W. Laurie, Michelle L. Matter, Lanlin Chen